Drugs for Castration-Resistant Prostate Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 217)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Prednisone |
Approved, Vet_approved |
Phase 4 |
|
53-03-2 |
5865 |
|
Synonyms:
1,2-Dehydrocortisone
1,4-Pregnadiene-17a,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17α,21-diol-3,11,20-trione
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
Acis brand OF prednisone
Acsis, prednison
Adasone
Ancortone
Apo-prednisone
Apotex brand OF prednisone
Aventis brand OF prednisone
Betapar
Bicortone
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
Cutason
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta-cortelan
Deltacortene
delta-Cortisone
Deltacortisone
Deltacortone
Delta-cortone
DELTA-DOME
Deltasone
Deltison
Deltisona
Deltisone
Deltra
Diadreson
Di-Adreson
Diba brand OF prednisone
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fawns and mcallan brand OF prednisone
FERNISONE
Ferring brand OF prednisone
Fiasone
GALENpharma brand OF prednisone
Halsey drug brand OF prednisone
Hexal brand OF prednisone
Hoechst brand OF prednisone
Hostacortin
ICN brand OF prednisone
Incocortyl
In-Sone
Juvason
Kortancyl
Lichtenstein brand OF prednisone
|
Liquid pred
Lisacort
LODOTRA
Lodotra®|Sterapred®
Me-Korti
Merck brand OF prednisone
Merz brand OF prednisone
Metacortandracin
Meticorten
Mibe brand OF prednisone
Nisona
Nizon
Novoprednisone
NSC-10023
Nurison
Orasone
Origen Prednisone
Panafcort
Panasol
PARACORT
Parmenison
Pehacort
Pharmacia brand OF prednisone
PRD
Precort
Predeltin
PREDN
Predni tablinen
PREDNICEN-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Predniment
Prednison
Prednison acsis
Prednison galen
Prednison hexal
Prednisona
Prednisona [INN-Spanish]
Prednisone
PREDNISONE INTENSOL
PREDNISONE TABLETS
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Pronison
Pronisone
RAYOS
Rectodelt
Retrocortine
Schering-plough brand OF prednisone
Seatrace brand OF prednisone
SERVISONE
Solvay brand OF prednisone
Sone
Sterapred
Supercortil
Trommsdorff brand OF prednisone
Ultracorten
Ultracortene
Winpred
Wojtab
Zenadrid
|
|
| 2 |
|
Antineoplastic Agents, Hormonal |
|
Phase 4 |
|
|
|
| 3 |
|
Hormones |
|
Phase 4 |
|
|
|
| 4 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
| 5 |
|
glucocorticoids |
|
Phase 4 |
|
|
|
| 6 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
| 7 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 4 |
|
|
|
| 8 |
|
Androgens |
|
Phase 4 |
|
|
|
| 9 |
|
Leuprolide |
Approved, Investigational |
Phase 3 |
|
53714-56-0 |
657181 |
|
Synonyms:
(D-Leu(6),des-gly-NH2(10),pro-ethylamide(9))-gonadotropin-releasing hormone
ABBOTT-43818
ABBOTT-43818 FREE BASE
ABBOTT-43818|Fensolvi® (leuprolide acetate injectable suspension)|Lupron®|TAP-144
Acetate, leuprolide
CKD-841
Enantone
Leuprolide
Leuprolide acetate
Leuprolide monoacetate
Leuprolide, (DL-leu)-isomer
Leuprolide, (L-leu)-isomer
Leuprorelin
|
Leuprorelin acetate
Leuprorelina
Leuproreline
Leuprorelinum
L-Pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide
Lupron
Monoacetate, leuprolide
NSC-377526
PGlu-his-TRP-ser-tyr-D-leu-leu-arg-pro-NHC2H5
PGlu-his-TRP-ser-tyr-D-leu-leu-arg-pro-nhet
TAP 144
TAP-144
TAP-144 FREE BASE
|
|
| 10 |
|
Goserelin |
Approved |
Phase 3 |
|
65807-02-5 |
5311128 47725 |
|
Synonyms:
(2S)-1-[(2S)-2-{[(2S)-2-{[(2R)-3-(tert-butoxy)-2-{[(2S)-2-{[(2S)-1,3-dihydroxy-2-{[(2S)-1-hydroxy-2-{[(2S)-1-hydroxy-2-({hydroxy[(2S)-5-hydroxy-3,4-dihydro-2H-pyrrol-2-yl]methylidene}amino)-3-(1H-imidazol-5-yl)propylidene]amino}-3-(1H-indol-3-yl)propylidene]amino}propylidene]amino}-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-1-hydroxypropylidene]amino}-1-hydroxy-4-methylpentylidene]amino}-5-carbamimidamidopentanoyl]-N-[(C-hydroxycarbonimidoyl)amino]pyrrolidine-2-carboximidate
Acetate, goserelin
DECAPEPTIDE I
decapeptide I|ICI 118630|Zoladex®
Goserelin
Goserelin acetate
Goserelina
|
ICI 118
ICI 118630
ICI-118630
ICI-118630Zoladex
ZD9393
Zoladex
|
|
| 11 |
|
Rucaparib |
Approved, Investigational |
Phase 3 |
|
283173-50-2 |
9931954 |
|
Synonyms:
AG014699
AG-014699
AG-014699|AG014699|AG14447|PF-01367338|Rubraca®
AG14447
AG-14447
|
AG-14447ag-014699Rucaparib
PF-01367338
Rubraca
RUCAPARIB
Rucaparibum
|
|
| 12 |
|
Carbamide peroxide |
Approved |
Phase 2, Phase 3 |
|
124-43-6 |
|
|
Synonyms:
Carbamide peroxide
Hydrogen peroxide carbamide
Urea dioxide
|
Urea hydrogen peroxide
Urea peroxide
|
|
| 13 |
|
Edetate calcium disodium anhydrous |
Approved, Vet_approved |
Phase 2, Phase 3 |
|
62-33-9, 60-00-4 |
6049 |
|
Synonyms:
(Ethylenedinitrilo)tetraacetate, ion(4-)
(ethylenedinitrilo)tetraacetic acid, ion(4−)
(Ethylenedinitrilo)tetraacetic acid, ion(4-)
{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetate
{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetIC ACID
2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate
2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetic acid
Acid, edetic
Acid, ethylenediaminetetraacetic
Acid, ethylenedinitrilotetraacetic
Acide edetique
Acide ethylenediaminetetracetique
Acido edetico
Acidum edeticum
CaEDTA
Calcioedetato de sodio
Calcitetracemate, disodium
Calcium disodium edetate
Calcium disodium edetic acid
Calcium disodium edta
Calcium disodium ethylenediamine tetraacetate
Calcium disodium ethylenediamine tetraacetic acid
Calcium disodium ethylenediaminetetraacetate
Calcium disodium ethylenediaminetetraacetic acid
Calcium disodium versenate
Calcium disodium versenic acid
Calcium edetate de sodium
CALCIUM EDETATE SODIUM
Calcium edetic acid de sodium
Calcium edta
Calcium sodium 2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate (1/2/1)
Calcium sodium 2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetic acid (1/2/1)
CALCIUM SODIUM EDETATE HYDRATE
Calcium sodium edta
Calcium tetacine
CaNa2Edta
Chelaton 3
Chromium edta
Copper edta
Coprin
Dicobalt edta
Dinitrilotetraacetate, disodium ethylene
Dinitrilotetraacetate, ethylene
Disodium calcitetracemate
Disodium calcium edta
Disodium calcium ethylenediaminetetraacetate
Disodium calcium ethylenediaminetetraacetic acid
Disodium edta
Disodium ethylene dinitrilotetraacetate
Disodium monocalcium edta
Disodium versenate, calcium
Distannous edta
E385
Edathamil
Edetate
Edetate calcium
Edetate calcium disodium
Edetate calcium disodium (anhydrous)
Edetate disodium calcium
Edetate, calcium disodium
Edetates
|
Edetic acid
Edetic acid calcium disodium
Edetic acid calcium disodium (anhydrous)
Edetic acid calcium disodium salt
Edetic acid, calcium salt
Edetic acid, calcium, sodium salt
Edetic acid, chromium salt
Edetic acid, dipotassium salt
Edetic acid, disodium salt
Edetic acid, disodium salt, dihydrate
Edetic acid, disodium, magnesium salt
Edetic acid, disodium, monopotassium salt
Edetic acid, magnesium salt
Edetic acid, monopotassium salt
Edetic acid, monosodium salt
Edetic acid, potassium salt
Edetic acid, sodium salt
EDT
EDTA
EDTA CALCIUM DISODIUM
EDTA calcium disodium salt
EDTA disodium calcium salt
EDTA, calcium derivative, disodium salt
EDTA, chromium
EDTA, copper
EDTA, dicobalt
EDTA, disodium
EDTA, distannous
EDTA, gallium
EDTA, ion(4-)
EDTA, magnesium disodium
EDTA, potassium
EDTA, stannous
EDTHAMIL
Ethylene dinitrilotetraacetate
Ethylene dinitrilotetraacetate, disodium
Ethylenediaminetetraacetate
Ethylenediaminetetraacetate calcium disodium salt
Ethylenediaminetetraacetic acid
Ethylenediaminetetraacetic acid calcium disodium salt
Ethylenedinitrilotetraacetic acid
Gallium edta
H4EDta
Magnesium disodium edta
Monocalcium disodium edta
N,N'-1,2-ethane diylbis-(N-(carboxymethyl)glycine)
N,N'-1,2-ethanediylbis(N-(carboxymethyl)glycine)
Natrii calcii edetas
Potassium edta
Sodium calcium edetate
Sodium calcium edetic acid
SODIUM CALCIUMEDETATE
Stannous edta
Tetacine, calcium
Tetracemate
Versenate
Versenate, calcium disodium
Versene
Versene acid
VERSENE CA
|
|
| 14 |
|
Pentetic acid |
Approved |
Phase 2, Phase 3 |
|
67-43-6 |
|
|
Synonyms:
[[(Carboxymethyl)imino]bis(1,2-ethanediylnitrilo)tetraacetate]
[[(Carboxymethyl)imino]bis(1,2-ethanediylnitrilo)tetraacetic acid]
1,1,4,7,7-Diethylenetriaminepentaacetate
1,1,4,7,7-Diethylenetriaminepentaacetic acid
Ca-dtpa
CaDTPA
Calcium trisodium pentetate
CaNa-dtpa
Complexon V
DETAPAC
Diethylene triamine pentaacetic acid
Diethylenetriamine pentaacetic acid
Diethylenetriamine-N,N,n',n'',n''-pentaacetate
Diethylenetriamine-N,N,n',n'',n''-pentaacetic acid
Diethylenetriaminepentaacetate
Diethylenetriaminepentaacetic acid
Diethylenetriaminepentacetate
Diethylenetriaminepentacetic acid
DTPA
DTP-A
H5dTpa
Indium dtpa
|
Indium-dtpa
MN-Dtpa
N,N,N',n'',n''-diethylenetriaminepentaacetate
N,N,N',n'',n''-diethylenetriaminepentaacetic acid
N,N-Bis[2-[bis(carboxymethyl)amino]ethyl]glycine
NSC-7340
Pentaacetic acid, diethylenetriamine
Pentacarboxymethyldiethylenetriamine
Pentacin
Pentacine
Pentaind
Pentetate
Pentetate calcium trisodium
Pentetate zinc trisodium
Pentetate, calcium trisodium
Pentetates
PENTETIC ACID
Penthanil
sn-DTPA
Titriplex V
Zinc dtpa
Zinc-dtpa
|
|
| 15 |
|
Niraparib |
Approved, Investigational |
Phase 3 |
|
1038915-60-4 |
24958200 |
|
Synonyms:
COMPOUND 56 [PMID 19873981]
compound 56 [PMID 19873981]|MK 4827|MK-4827|Zejula®
JNJ-64091742
MK 4827
|
MK4827
MK-4827
NIRAPARIB
ZL-2306
|
|
| 16 |
|
Atezolizumab |
Approved, Investigational |
Phase 3 |
|
1380723-44-3 |
|
|
Synonyms:
ANTI-PDL1
ANTI-PD-L1
ATEZOLIZUMAB
MPDL3280A
|
MPDL-3280A
RG-7446
TECENTRIQ
|
|
| 17 |
|
Lysine |
Approved, Nutraceutical |
Phase 2, Phase 3 |
|
56-87-1 |
5962 |
|
Synonyms:
(+)-S-Lysine
(S)-2,6-Diaminohexanoate
(S)-2,6-Diamino-hexanoate
(S)-2,6-Diaminohexanoic acid
(S)-2,6-Diamino-hexanoic acid
(S)-a,e-Diaminocaproate
(S)-a,e-Diaminocaproic acid
(S)-a,epsilon-Diaminocaproate
(S)-a,epsilon-Diaminocaproic acid
(S)-alpha,epsilon-Diaminocaproate
(S)-alpha,epsilon-Diaminocaproic acid
(S)-Lysine
(S)-Α,epsilon-diaminocaproate
(S)-Α,epsilon-diaminocaproic acid
(S)-α,ε-diaminocaproic acid
2,6-Diaminohexanoate
2,6-Diaminohexanoic acid
6-Amino-aminutrin
6-Amino-L-norleucine
6-Ammonio-L-norleucine
Acetate, lysine
alpha-Lysine
|
a-Lysine
Aminutrin
Enisyl
H-Lys-OH
K
L Lysine
L-(+)-Lysine
L-2,6-Diainohexanoate
L-2,6-Diainohexanoic acid
L-2,6-Diaminocaproate
L-2,6-Diaminocaproic acid
L-Lys
L-Lysin
L-Lysine
Lys
Lysina
Lysine
Lysine acetate
Lysine acid
Lysine hydrochloride
Lysinum
|
|
| 18 |
|
Choline |
Approved, Nutraceutical |
Phase 2, Phase 3 |
|
62-49-7 |
305 |
|
Synonyms:
(2-Hydroxyethyl)trimethyl ammonium
(2-Hydroxyethyl)trimethylammonium
(2-HYDROXYETHYL)TRIMETHYLAZANIUM
(beta-Hydroxyethyl)trimethylammonium
2-HYDROXYETHYL-TRIMETHYL-AMMONIUM
2-HYDROXYETHYL-TRIMETHYL-AZANIUM
2-Hydroxy-N,N,N-trimethylethanaminium
2-Hydroxy-N,N,N-trimethyl-ethanaminium
Bilineurine
Biocolina
Biocoline
Bitartrate, choline
Bursine
Chloride, choline
CHOLINE
Choline bitartrate
Choline cation
Choline chloride
Choline citrate
Choline hydroxide
|
CHOLINE ion
Choline O sulfate
Choline O-sulfate
Cholinum
Citrate, choline
Fagine
Hepacholine
Hormocline
Hydroxide, choline
Lipotril
N,N,N-Trimethylethanolammonium
N,N,N-Trimethylethanol-ammonium
Neocolina
N-Trimethylethanolamine
O-Sulfate, choline
Paresan
Trimethylethanolamine
Vidine
Vitamin J
|
|
| 19 |
|
Calcium, Dietary |
|
Phase 2, Phase 3 |
|
|
|
| 20 |
|
Anticoagulants |
|
Phase 2, Phase 3 |
|
|
|
| 21 |
|
Chelating Agents |
|
Phase 2, Phase 3 |
|
|
|
| 22 |
|
Poly(ADP-ribose) Polymerase Inhibitors |
|
Phase 3 |
|
|
|
| 23 |
|
Immunoglobulins |
|
Phase 3 |
|
|
|
| 24 |
|
Antibodies |
|
Phase 3 |
|
|
|
| 25 |
|
Taxane |
|
Phase 3 |
|
|
108169 |
| 26 |
|
Antimetabolites |
|
Phase 2, Phase 3 |
|
|
|
| 27 |
|
Abiraterone Acetate |
|
Phase 2, Phase 3 |
|
154229-18-2 |
9821849 |
|
Synonyms:
ABIRATERONE ACETATE
CB-7630
|
|
|
| 28 |
|
Gastrointestinal Agents |
|
Phase 2, Phase 3 |
|
|
|
| 29 |
|
Hypolipidemic Agents |
|
Phase 2, Phase 3 |
|
|
|
| 30 |
|
Lipid Regulating Agents |
|
Phase 2, Phase 3 |
|
|
|
| 31 |
|
Nootropic Agents |
|
Phase 2, Phase 3 |
|
|
|
| 32 |
|
Calcium |
Nutraceutical |
Phase 2, Phase 3 |
|
7440-70-2 |
271 |
|
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
| 33 |
|
Durvalumab |
Approved, Investigational |
Phase 2 |
|
1428935-60-7 |
|
|
Synonyms:
|
| 34 |
|
Tremelimumab |
Approved, Investigational |
Phase 2 |
|
745013-59-6 |
|
|
Synonyms:
CP-675,206
CP-675|CP-675,206|CP-675206|ticilimumab
CP-675206
|
TICILIMUMAB
TREMELIMUMAB
TREMELIMUMAB (GENETICAL RECOMBINATION)
|
|
| 35 |
|
Nivolumab |
Approved |
Phase 2 |
|
946414-94-4 |
|
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
| 36 |
|
Talazoparib |
Approved, Investigational |
Phase 2 |
|
1207456-01-6 |
135565082 |
|
Synonyms:
BMN 673
BMN-673
BMN-673|BMN673|Talzenna®
|
LT-673
TALAZOPARIB
Talzenna
|
|
| 37 |
|
Adenosine |
Approved, Investigational |
Phase 1, Phase 2 |
|
58-61-7 |
60961 |
|
Synonyms:
(2R,3R,4R,5R)-2-(6-AMINOPURIN-9-YL)-5-(HYDROXYMETHYL)OXOLANE-3,4-DIOL
(2R,3R,4R,5R)-2-(6-AMINOPURIN-9-YL)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-3,4-DIOL
(2R,3R,4R,5R)-2-(6-AMINOPURIN-9-YL)-5-METHYLOL-TETRAHYDROFURAN-3,4-DIOL
(2R,3R,4S,5R)-2-(6-AMINO-9H-PURIN-9-YL)-5-(HYDROXYMETHYL)OXOLANE-3,4-DIOL
(2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
1-(6-Amino-9H-purin-9-yl)-1-deoxy-beta-delta-ribofuranose
1-(6-Amino-9H-purin-9-yl)-1-deoxy-beta-D-ribofuranose
6-Amino-9-b-D-ribofuranosyl-9H-purine
6-Amino-9beta-delta-ribofuranosyl-9H-purine
6-Amino-9beta-D-ribofuranosyl-9H-purine
6-Amino-9-beta-D-ribofuranosyl-9H-purine
6-Amino-9-β-D-ribofuranosyl-9H-purine
9-b-D-Ribofuranosidoadenine
9-b-D-Ribofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyladenine
9-beta-delta-Arabinofuranosyladenine
9-beta-delta-Ribofuranosidoadenine
9beta-delta-Ribofuranosyl-9H-purin-6-amine
9-beta-delta-Ribofuranosyl-9H-purin-6-amine
9beta-delta-Ribofuranosyladenine
9-beta-delta-Ribofuranosyladenine
9-beta-D-Ribofuranosidoadenine
9beta-D-Ribofuranosyl-9H-purin-6-amine
9-beta-D-Ribofuranosyl-9H-purin-6-amine
9beta-D-Ribofuranosyladenine
9-beta-D-Ribofuranosyladenine
9-Β-D-ribofuranosidoadenine
9-Β-D-ribofuranosyl-9H-purin-6-amine
ADENIN RIBOSIDE
Adenine deoxyribonucleoside
|
Adenine nucleoside
Adenine riboside
Adenine-9beta-delta-ribofuranoside
Adenine-9beta-D-ribofuranoside
Adenocard
Adenocard®|Adenoscan®
Adenocor
ADENOGESIC
Adenoscan
Adenosin
ADENOSINA
ADENOSINE
ADÉNOSINE
ADENOSINUM
Adenyldeoxyriboside
Ade-rib
Ado
b-D-Adenosine
beta-Adenosine
beta-D-Adenosine
beta-delta-Adenosine
Boniton
Deoxyadenosine
Desoxyadenosine
Myocol
NSC-7652
Nucleocardyl
Sandesin
SR-96225
Β-D-adenosine
|
|
| 38 |
|
Irinotecan |
Approved, Investigational |
Phase 1, Phase 2 |
|
97682-44-5, 100286-90-6 |
60838 |
|
Synonyms:
(+)-Irinotecan
7 Ethyl 10 hydroxycamptothecin
7-Ethyl-10-hydroxycamptothecin
Biotecan
Camptosar
Camptothecin 11
Camptothecin-11
CP0
CPT 11
CPT11
CPT-11
HSDB 7607
Irinophore C
IRINOTECAN
|
Irinotecan Hcl
Irinotecan hydrochloride
Irinotecan hydrochloride trihydrate
Irinotecan lactone
Irinotecan mylan
IRINOTECAN, CPT-11
Irinotecanum
Irinotecanum [INN-Latin]
Irrinotecan
NK012 Compound
sn 38
sn-38
sn38 CPD
|
|
| 39 |
|
Esomeprazole |
Approved, Investigational, Vet_approved |
Phase 2 |
|
73590-58-6, 119141-88-7 |
9568614 4594 |
|
Synonyms:
( -)-Omeprazole
(−)-omeprazole
(-)-Omeprazole
(S)-(−)-omeprazole
(S)-(-)-Omeprazole
(S)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole
(S)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole
(S)-Omeprazole
(S)-omeprazole|Nexium®
2,3,5-Trimethylpyridine/Omeprazole
A02BC05
Alenia
Antra
Antra mups
AstraZeneca brand OF esomeprazole magnesium
Audazol
Aulcer
Axagon
Belmazol
Ceprandal
Danlox
Demeprazol
Desec
Dizprazol
Dudencer
Elgam
Emeproton
EMOZUL
Epirazole
Erbolin
Escz
Esofag
Esomeprazol
Esomeprazole
Ésoméprazole
Esomeprazole magnesium
Esomeprazole potassium
Esomeprazole sodium
Esomeprazole strontium
Esomeprazole strontium anhydrous
Esomeprazolum
Esomperazole
Esopral
Exter
Gasec
Gastrimut
Gastroloc
Gibancer
H 168/68
H 168/68|Losec®|Prilosec®
H-168/68
Indurgan
Inexium paranova
Inhibitron
Inhipump
Lensor
Logastric
Lomac
Losec
LOSEC MUPS
Lucen
Magnesium, omeprazole
Mepral
MEZZOPRAM
Miol
Miracid
Mopral
Morecon
Nexiam
Nexium
NEXIUM CONTROL
NEXIUM I.V.
Nexium IV
Nilsec
Nopramin
|
Nuclosina
Ocid
Olexin
Omapren
Omebeta 20
Omed
Omegast
OMEP
Omepradex
Omepral
Omeprazol
Omeprazol [INN-Spanish]
Omeprazole
Omeprazole magnesium
Omeprazole pellets
Omeprazole S-form
Omeprazole sodium
Omeprazolum
Omeprazolum [INN-Latin]
Omeprazon
Omeprol
OMERAN
Omesek
Omez
Omezol
Omezolan
Omid
Omisec
Omizac
OMP
Ompanyt
OMZ
Ortanol
Osiren
Ozoken
Paprazol
Parizac
Pepticum
Pepticus
Peptilcer
Perprazole
Prazentol
Prazidec
Prazolit
Prestwick_808
Prilosec
Prilosec otc
Procelac
Proclor
Prysma
Ramezol
Regulacid
Result
Sanamidol
Secrepina
Sodium, omeprazole
Strontium, esomeprazole
Tedec ulceral
Ulceral
Ulcesep
Ulcometion
Ulcozol
Ulcsep
Ulsen
Ultop
Ulzol
VENTRA
Victrix
ZANPROL
Zefxon
Zegerid
Zepral
Zimor
Zoltum
|
|
| 40 |
|
Altretamine |
Approved |
Phase 2 |
|
645-05-6 |
2123 |
|
Synonyms:
2,4,6-Tris(dimethylamino)-1,3,5-triazine
2,4,6-Tris(dimethylamino)-S-triazine
ALTRETAMIN
Altretamina
Altretamine
ALTRÉTAMINE
Altretamine bellon brand
Altretamine chiesi brand
Altretamine wassermann brand
Altretaminum
Bellon brand OF altretamine
Chiesi brand OF altretamine
Hemel
|
Hexalen
HEXAMETHYLMELAMINE
Hexastat
Hexinawas
HMM
HTM
HXM
MGI pharma brand OF altretamine
NSC-13875
Rhône poulenc rorer brand OF altretamine
Rhône-poulenc rorer brand OF altretamine
Wassermann brand OF altretamine
|
|
| 41 |
|
Pembrolizumab |
Approved |
Phase 2 |
|
1374853-91-4 |
254741536 |
|
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
| 42 |
|
Olaparib |
Approved |
Phase 2 |
|
763113-22-0 |
23725625 |
|
Synonyms:
1-(CYCLOPROPYLCARBONYL)-4-[5-[(3,4-DIHYDRO-4-OXO-1-PHTHALAZINYL)METHYL]-2-FLUOROBENZOYL]PIPERAZINE
4-(3-{[4-(CYCLOPROPYLCARBONYL)PIPERAZIN-1-YL]CARBONYL}-4-FLUOROBENZYL)PHTHALAZIN-1(2H)-ONE
AZ2281
AZ-2281
AZD2281
AZD-2281
AZD-2281|AZD2281|Lynparza®
|
KEYLYNK-010 COMPONENT OLAPARIB
KU-0059436
KU59436
KU-59436
Lynparza
OLAPARIB
OLAPARIB COMPONENT OF KEYLYNK-010
|
|
| 43 |
|
Iron |
Approved |
Phase 2 |
|
7439-89-6 |
29936 |
|
Synonyms:
Carbonyl iron
Eisen
Electrolytic iron
Fe
FE (III) ion
Fe(3+)
Fe(III)
fer
Ferric ion
Ferric iron
Ferrum
|
Ferrum metallicum
Hierro
Iron powder
Iron(3+)
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (fe(3+))
Iron, reduced
Reduced iron
|
|
| 44 |
|
Ipilimumab |
Approved |
Phase 2 |
|
477202-00-9 |
|
|
Synonyms:
BMS-734016
Ipilimumab
MDX-010
MDX-010|MDX-101|MDX-CTLA-4|Yervoy®
|
MDX-101
MDX-CTLA-4
MOAB-CTLA-4
YERVOY
|
|
| 45 |
|
Avelumab |
Approved, Investigational |
Phase 1, Phase 2 |
|
1537032-82-8 |
|
|
Synonyms:
AVELUMAB
BAVENCIO
MSB0010682
|
|
|
| 46 |
|
Testosterone |
Approved, Investigational |
Phase 2 |
|
58-22-0 |
5408 6013 |
|
Synonyms:
(+-)-8-ISO-TESTOSTERONE
(+-)-RETROTESTOSTERONE
(+)-TESTOSTERONE
(+-)-TESTOSTERONE
(17B)-17-HYDROXY-ANDROST-4-EN-3-ONE
(1S,2R,10R,11S,14S,15S)-14-HYDROXY-2,15-DIMETHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADEC-6-EN-5-ONE
13-ISO-TESTOSTERONE
17 beta Hydroxy 4 androsten 3 one
17 beta Hydroxy 8 alpha 4 androsten 3 one
17A-HYDROXY-(13A)-ANDROST-4-EN-3-ONE
17A-HYDROXY-13A-ANDROST-4-EN-3-ONE
17A-HYDROXY-14B-ANDROST-4-EN-3-ONE
17A-HYDROXY-ANDROST-4-EN-3-ONE
17-beta-Hydroxy-4-androsten-3-one
17BETA-HYDROXY-4-ANDROSTEN-3-ONE
17-beta-Hydroxy-8 alpha-4-androsten-3-one
17B-HYDROXY-(10A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(13A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(8A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(8A,10A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(9B)-ANDROST-4-EN-3-ONE
17B-HYDROXY-(9B,10A)-ANDROST-4-EN-3-ONE
17B-HYDROXY-13A-ANDROST-4-EN-3-ONE
17b-Hydroxy-4-androsten-3-one
17B-HYDROXY-8A-ANDROST-4-EN-3-ONE
17B-HYDROXY-ANDROST-4-EN-3-ON
17B-HYDROXYANDROST-4-EN-3-ONE
17B-HYDROXY-ANDROST-4-EN-3-ONE
17B-HYDROXYANDROST-4-ENE-3-ONE
17B-HYDROXY-D4-ANDROSTEN-3-ONE
17B-TESTOSTERONE
17-HYDROXY-10,13-DIMETHYL-1,2,6,7,8,9,10,11,12,13,14,15,16,17-TETRADECAHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE
17-HYDROXY-ANDROST-4-EN-3-ONE
17-HYDROXY-D4-ANDROSTEN-3-ONE
17Β-hydroxy-4-androsten-3-one
4-ANDROSTEN-17BETA-OL-3-ONE
4-Androsten-17b-ol-3-one
4-ANDROSTEN-17Β-OL-3-ONE
4-ANDROSTEN-3-ONE-17B-OL
8 Isotestosterone
8-Isotestosterone
8-ISO-TESTOSTERONE
9B,10A-TESTOSTERONE
9B-TESTOSTERONE
Andriol
Andro
Andro 100
Andro L.A. 200
ANDRODERM
Androderm®|Delatestryl®
ANDROGEL
ANDROGEL 1%
Android 10
Android 25
Android 5
Androlin
Andronaq
Andronate 100
Andronate 200
ANDROPATCH
Andropository 200
Androsorb
ANDROST-4-EN-17B-OL-3-ONE
ANDROST-4-ENE-17B-OL-3-ONE
Androtop
Andrusol
Andryl 200
AstraZeneca brand OF testosterone
Auxilium pharmaceuticals inc. brand OF testosterone
AXIRON
Bartor brand OF testosterone
Beta Testosterone
Bio-T-Gel
CDB 111C
CEPA brand OF testosterone
Cristerona T
Cristerone T
D4-ANDROSTEN-17B-OL-3-ONE
Dea No. 4000
Delatest
DELATESTRYL
Depotest
Depo-Testosterone
Depo-Testosterone Cypionate
Dr. kade brand OF testosterone
Epitestosteron
Everone 200
Faulding brand OF testosterone
Ferring brand OF testosterone
FORTESTA
Geno-cristaux gremy
GlaxoSmithKline brand OF testosterone
Hauck brand OF testosterone
Histerone
Homosteron
Homosterone
INTRINSA
Libigel
LUMITESTOSTERON
|
Malerone
Malestrone
Malogen in Oil
Malogen, Aquaspension Injection
MERTESTATE
Metandren
Methyltestosterone
NATESTO
Neo-Hombreol F
Neotestis
Neo-Testis
NSC-9700
Oreton
Oreton F
Oreton Methyl
Oreton-F
Orquisteron
Ortho brand OF testosterone
Paladin brand OF testosterone
Pasadena brand OF testosterone
Perandren
Percutacrine androgenique
Primotest
Primoteston
RAC-17B-HYDROXY-(13A)ANDROST-4-EN-3-ONE
RAC-17B-HYDROXY-(8A)-ANDROST-4-EN-3-ONE
RAC-17B-HYDROXY-(9B,10A)ANDROST-4-EN-3-ONE
RAC-17B-HYDROXY-ANDROST-4-EN-3-ONE
Relibra
RETROTESTOSTERONE
Scheinpharm Testone-Cyp
Schering brand OF testosterone
SmithKline beecham brand OF testosterone
Solvay brand OF testosterone
Sterotate
STRIANT
STRIANT SR
Sustanon
Sustanone
Sustason 250
Synandrol F
T-Cypionate
TES
Teslen
Testamone 100
Testandrone
Testaqua
Testiculosterone
TESTIM
TESTIM 1%
Testobase
TESTODERM
TESTODERM TTS
TESTOGEL
Testoject-50
Testolent
Testolin
TESTOPATCH
TESTOPEL
Testopel Pellets
Testopropon
TESTORAL
Testosteroid
TESTOSTERON
TESTOSTERONA
Testosterona [INN-Spanish]
TESTOSTERONE
TESTOSTÉRONE
TESTOSTERONE CIII
Testosterone Cypionate
Testosterone Enanthate
Testosterone Hydrate
Testosterone sulfate
TESTOSTERONUM
Testosteronum [INN-Latin]
Testostosterone
Testoviron
Testoviron schering
Testoviron T
Testred
Testred Cypionate 200
Testrin-P.A
Testro aq
TESTRONE
Testryl
TOSTRAN
Tostrelle
Tostrex
Trans-Testosterone
Ulmer brand OF testosterone
Unimed brand OF testosterone
Viatrel
Virilon
Virilon IM
Virormone
VIROSTERONE
VOGELXO
Watson brand OF testosterone
|
|
| 47 |
|
Methyltestosterone |
Approved |
Phase 2 |
|
58-18-4 |
6010 |
|
Synonyms:
17 alpha Methyltestosterone
17 beta Hydroxy 17 methyl 4 androsten 3 one
17 beta Methyltestosterone
17 beta-Hydroxy-17-methyl-4-androsten-3-one
17 beta-Methyltestosterone
17 Epimethyltestosterone
17(a)-Methyl-delta(4)-androsten-17(b)-ol-3-one
17(a)-Methyl-δ(4)-androsten-17(b)-ol-3-one
17(alpha)-Methyl-Delta(4)-androsten-17(beta)-ol-3-one
17(Α)-methyl-δ(4)-androsten-17(β)-ol-3-one
17alpha Methyl testosterone
17alpha Methyltestosterone
17alpha-Methyl-3-oxo-4-androsten-17beta-ol
17alpha-Methyl-Delta(4)-androsten-17beta-ol-3-one
17alpha-Methyl-delta-androsten-17beta-ol-3-one
17alpha-Methyltestosterone
17alpha-Methyl-testosterone
17-alpha-Methyltestosterone
17a-Methyl-3-oxo-4-androsten-17b-ol
17a-Methyl-delta(4)-androsten-17b-ol-3-one
17a-Methyltestosterone
17a-Methyl-δ(4)-androsten-17b-ol-3-one
17beta Hydroxy 17 methyl 4 androsten 3 one
17beta Methyltestosterone
17beta-Hydroxy-17-methyl-4-androsten-3-one
17beta-Hydroxy-17-methylandrost-4-en-3-one
17-beta-Hydroxy-17-methylandrost-4-en-3-one
17beta-Methyltestosterone
17b-Hydroxy-17-methylandrost-4-en-3-one
17-b-Hydroxy-17-methylandrost-4-en-3-one
17-Epimethyltestosterone
17-Methyltestosterone
17Α-methyl-3-oxo-4-androsten-17β-ol
17Α-methyltestosterone
17Α-methyl-δ(4)-androsten-17β-ol-3-one
17Α-METHYL-Δ4-ANDROSTEN-17Β-OL-3-ONE
17Β-hydroxy-17-methylandrost-4-en-3-one
17-Β-hydroxy-17-methylandrost-4-en-3-one
4-Androstene-17alpha-methyl-17beta-ol-3-one
4-Androstene-17a-methyl-17b-ol-3-one
|
4-Androstene-17α-methyl-17β-ol-3-one
Android
Android (methyltestoterone)
Android 10
Android 25
Android 5
Android-10
Android-25
Android-5
CDB-110
Global pharmaceutical brand OF methyltestosterone
ICN brand 1 OF methyltestosterone
ICN brand 2 OF methyltestosterone
L 589.372
L-589.372
L-589372
Mesteron
Mesterone
Metandren
Methitest
Methyltestosterone
METHYLTESTOSTERONE CIII
Methyltestosteronum
Metiltestosterona
NSC-139965
NSC-9701
Oreton
ORETON METHYL
PERANDREN
PLEX HORMONE
POTENSAN FTE
RU 24400
RU-24400
Schering brand OF methyltestosterone
Star brand OF methyltestosterone
Testoviron
TESTOVIS
Testred
U-2842
Virilon
|
|
| 48 |
|
Testosterone undecanoate |
Approved, Investigational |
Phase 2 |
|
5949-44-0 |
21873174 65157 |
|
Synonyms:
2,15-Dimethyl-5-oxotetracyclo[8.7.0.0,.0,]heptadec-6-en-14-yl undecanoic acid
ANDRIOL
AVEED
JATENZO
MK-3033
NEBIDO
ORG-538
RESTANDOL
|
RESTANDOL TESTOCAP
Testosterone undecanoate
Testosterone undecanoic acid
Testosterone undeconate
Testosterone undecylate
TSX-011
UNDESTOR
|
|
| 49 |
|
Testosterone enanthate |
Approved |
Phase 2 |
|
315-37-7 |
9416 |
|
Synonyms:
17-((1-Oxoheptyl)oxy)androst-4-en-3-one
17beta-Enanthoxyandrost-4-en-3-one
17beta-Hydroxyandrost-4-en-3-one enanthate
17beta-Hydroxyandrost-4-en-3-one heptanoate
17beta-Hydroxyandrost-4-en-3-one heptanoic acid
17b-Hydroxyandrost-4-en-3-one heptanoate
17b-Hydroxyandrost-4-en-3-one heptanoic acid
17-Hydroxyandrost-4-en-3-one, 17-heptanoate
17-Hydroxyandrost-4-en-3-one, 17-heptanoic acid
17Β-hydroxyandrost-4-en-3-one heptanoate
17Β-hydroxyandrost-4-en-3-one heptanoic acid
4-Androsten-17beta-ol-3-one 17-enanthate
4-Androsten-3-one 17beta-enanthate
Androgyn l.a.
Andropository
Androtardyl
Atlatest
BTG Brand OF testosterone enanthate
DEA no. 4000
Delatest
Delatestryl
DePatestrye
depo-testro Med
Ditate
Durathate
eifelfango Brand OF testosterone enanthate
Everone
Exten test
Jenapharm brand OF testosterone enanthate
Malogen l.a.
Malogen l.a.200
NSC-17591
Orquisteron-e
Pasadena brand OF testosterone enanthate
Primoteston depot
|
Primotestone
reposo TMD
Roberts brand OF testosterone enanthate
Rotexmedica brand OF testosterone enanthate
Rugby brand OF testosterone enanthate
Schering brand OF testosterone enanthate
Testanthate
Testate
Testenate
Testinon
Testoenant
Testonenant
Testosteron depot-rotexmedica
Testosteron-depot eifelfango
Testosteron-depot jenapharm
Testosterone 17beta-heptanoate
Testosterone 17beta-heptanoic acid
Testosterone 17-enanthate
Testosterone 17-enanthic acid
Testosterone enantate
Testosterone enanthate
TESTOSTERONE ENANTHATE CIII
Testosterone enanthic acid
Testosterone heptanoate
Testosterone heptanoic acid
Testosterone heptoate
Testosterone heptoic acid
Testosterone heptylate
Testosterone oenanthate
Testostroval
Testrin p.a.
Theramed brand OF testosterone enanthate
Theramex
XYOSTED (AUTOINJECTOR)
|
|
| 50 |
|
Carboplatin |
Approved |
Phase 1, Phase 2 |
|
41575-94-4 |
10339178 38904 |
|
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
Interventional clinical trials:
(show top 50)
(show all 120)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
Effect of a Reduced Dose on Cognitive Side Effects of Enzalutamide in Frail (Metastatic) Castration-resistant Prostate Cancer Patients (REDOSE) |
Recruiting |
NCT03927391 |
Phase 4 |
Enzalutamide |
| 2 |
Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer |
Recruiting |
NCT03016741 |
Phase 4 |
Prednisone;Abiraterone Acetate;Enzalutamide |
| 3 |
CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer |
Recruiting |
NCT04455750 |
Phase 3 |
Enzalutamide;Rucaparib camsylate;Placebo;Leuprolide Acetate;Goserelin Acetate;Degarelix |
| 4 |
A Phase 2/3, Randomized, Open-label, Study of MGC018 Versus Androgen Receptor Axis-targeted Therapy (Abiraterone or Enzalutamide) in Participants With Metastatic Castration-resistant Prostate Cancer |
Recruiting |
NCT05551117 |
Phase 2, Phase 3 |
ARAT |
| 5 |
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent |
Recruiting |
NCT04844749 |
Phase 3 |
VERU-111;Enzalutamide, Abiraterone |
| 6 |
Clinical Accuracy Assessment of 68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence |
Active, not recruiting |
NCT03822845 |
Phase 2, Phase 3 |
Ga-68 PSMA-HBED-CC PET |
| 7 |
A Phase III, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of an Androgen Synthesis Inhibitor and Failure of, Ineligibility for, or Refusal of a Taxane Regimen |
Active, not recruiting |
NCT03016312 |
Phase 3 |
Atezolizumab;Enzalutamide |
| 8 |
68Ga PSMA-HBED-CC in Intermediate to High-Risk Preprostatectomy Patients |
Active, not recruiting |
NCT03388346 |
Phase 2, Phase 3 |
Ga-68 PSMA-HBED-CC PET |
| 9 |
68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence |
Active, not recruiting |
NCT03389451 |
Phase 2, Phase 3 |
Ga-68 PSMA-HBED-CC PET |
| 10 |
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer |
Active, not recruiting |
NCT03748641 |
Phase 3 |
Niraparib;Abiraterone Acetate;Prednisone;Placebo;New Formulation of Niraparib and Abiraterone Acetate (AA) |
| 11 |
A Phase III, Randomised, Double-Blind, Placebo-Controlled Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer |
Terminated |
NCT02057666 |
Phase 3 |
Tasquinimod;Placebo |
| 12 |
F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer Treated by Abiraterone Acetate or Enzalutamide |
Terminated |
NCT01981707 |
Phase 2, Phase 3 |
|
| 13 |
Phase II Multi-Center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Castrate Resistant Prostate Cancer |
Unknown status |
NCT04159896 |
Phase 2 |
Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981 |
| 14 |
Phase II Open-label Study to Evaluate the Efficacy and Safety of Radium in Combination With External Beam Radiotherapy (EBRT) vs. EBRT Alone in the Treatment of Castration Resistant Prostate Carcinoma With Limited Bone Metastases |
Unknown status |
NCT02484339 |
Phase 2 |
Radium-223 dichloride |
| 15 |
A Phase II, Randomized, Multi-center Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer |
Unknown status |
NCT02254785 |
Phase 2 |
cabazitaxel;Abiraterone;Enzalutamide 160mg daily (oral) |
| 16 |
Docetaxel and Carboplatin for Patients With Metastatic, Castration Resistant Prostate Cancer and Inactivated Genes in BRCA 1/2 Pathway |
Completed |
NCT02598895 |
Phase 2 |
Carboplatin;Docetaxel |
| 17 |
Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard Therapy With Sipuleucel-T (Provenge®) in Pts w/ Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer(mCRPC) |
Completed |
NCT01881867 |
Phase 2 |
|
| 18 |
A Pilot Trial to Explore the Link Between Immunological Changes, Efficacy, Safety, and Tolerability of Durvalumab (MEDI4736) Plus Tremelimumab in Chemotherapy-Naïve Men With Metastatic Castration-Resistant Prostate Cancer (CRPC) |
Completed |
NCT03204812 |
Phase 2 |
|
| 19 |
A Randomized Gene Fusion Stratified Phase 2 Trial of Abiraterone With or Without ABT-888 for Patients With Metastatic Castration-Resistant Prostate Cancer |
Completed |
NCT01576172 |
Phase 2 |
Abiraterone Acetate;Prednisone;Veliparib |
| 20 |
An Open Label Phase I/II Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer |
Completed |
NCT01505868 |
Phase 1, Phase 2 |
Cabazitaxel;Carboplatin |
| 21 |
A Randomized, Open-label, Multicenter, Phase 2b Study to Evaluate Physical Function, Including Balance and Daily Activity, in Participants With Castration-resistant Prostate Cancer Treated With Darolutamide or Enzalutamide |
Completed |
NCT04157088 |
Phase 2 |
Darolutamide(Nubeqa, BAY1841788);Enzalutamide |
| 22 |
A Study of Erdafitinib in Castration-Resistant Prostate Cancer Patients Evaluating Markers of Bone Remodeling and FGF Signaling in Plasma and Bone Marrow |
Recruiting |
NCT04754425 |
Phase 2 |
Erdafitinib |
| 23 |
Phase I/II Study of CDK4/6 Inhibition With Abemaciclib to Upregulate PSMA Expression Prior to 177Lu-PSMA-617 Treatment in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Chemotherapy |
Recruiting |
NCT05113537 |
Phase 1, Phase 2 |
Abemaciclib;Lutetium Lu 177-PSMA-617 |
| 24 |
A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response |
Recruiting |
NCT04550494 |
Phase 2 |
Talazoparib |
| 25 |
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE) |
Recruiting |
NCT03317392 |
Phase 1, Phase 2 |
Olaparib |
| 26 |
68Ga-PSMA-11 PET in Patients With Prostate Cancer |
Recruiting |
NCT04777071 |
Phase 2 |
Gallium Ga 68 Gozetotide |
| 27 |
A Phase 2 Study of 68Ga-PSMA-11 PET in Patients With Metastatic Castration Resistant Prostate Cancer |
Recruiting |
NCT04716725 |
Phase 2 |
68Ga-PSMA-11 |
| 28 |
A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC) |
Recruiting |
NCT04071236 |
Phase 1, Phase 2 |
Avelumab;Peposertib |
| 29 |
Randomized Phase II Study of Platinum-Taxane-Cetrelimab Induction Followed by Niraparib Plus or Minus Cetrelimab Maintenance in Men With Aggressive Variant Prostate Cancers |
Recruiting |
NCT04592237 |
Phase 2 |
Cabazitaxel;Carboplatin;Niraparib |
| 30 |
A Phase 2 Study of BET Bromodomain Inhibitor ZEN-3694 in Combination With Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate Cancer |
Recruiting |
NCT04471974 |
Phase 2 |
BET Bromodomain Inhibitor ZEN-3694;Enzalutamide |
| 31 |
Erdafitinib Plus Abiraterone Acetate or Enzalutamide in Double Negative Prostate Cancer |
Recruiting |
NCT03999515 |
Phase 2 |
Abiraterone Acetate;Enzalutamide;Erdafitinib |
| 32 |
AtezoCab: A Phase II Study of Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Non-Measurable Disease |
Recruiting |
NCT05168618 |
Phase 2 |
Cabozantinib S-malate |
| 33 |
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial |
Recruiting |
NCT03419234 |
Phase 2 |
Abiraterone Acetate;Antiandrogen Therapy;Cabazitaxel;Prednisone |
| 34 |
A Randomized, Phase II Study of Apalutamide +/- Stereotactic Body Radiotherapy (SBRT) in Castration-Resistant Prostate Cancer Patients With Oligometastatic Disease on PSMA-PET Imaging |
Recruiting |
NCT03503344 |
Phase 2 |
Apalutamide |
| 35 |
Olaparib in Prostate Cancer Patients With Evidence of Homologous Recombination Deficiency as Assessed Using an Integrated Genomic Signature |
Recruiting |
NCT04951492 |
Phase 2 |
Olaparib |
| 36 |
PLATI-PARP: A Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in Treatment of Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency |
Recruiting |
NCT03442556 |
Phase 2 |
Carboplatin;Docetaxel;Rucaparib Camsylate;Rucaparib |
| 37 |
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer |
Recruiting |
NCT04381832 |
Phase 1, Phase 2 |
Etrumadenant;Zimberelimab;Quemliclustat;Enzalutamide;Docetaxel;SG |
| 38 |
Phase 2 INSPIRE Trial: Ipilimumab With Nivolumab for Molecular- Selected Patients With Castration-resistant Prostate Cancer |
Recruiting |
NCT04717154 |
Phase 2 |
|
| 39 |
A Phase 1/2 Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas |
Recruiting |
NCT04104776 |
Phase 1, Phase 2 |
CPI-0209 |
| 40 |
A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer |
Recruiting |
NCT05169684 |
Phase 2 |
Docetaxel |
| 41 |
A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer |
Recruiting |
NCT04868604 |
Phase 1, Phase 2 |
64Cu-SAR-bisPSMA;67Cu-SAR-bisPSMA |
| 42 |
FASN Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer Salvaging Taxane Failure |
Recruiting |
NCT04337580 |
Phase 2 |
Omeprazole 80 mg twice daily |
| 43 |
A Randomised Non-comparative Phase II Trial of Biomarker-driven Intermittent Docetaxel Versus Standard-of-care (SOC) Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC) |
Recruiting |
NCT04918810 |
Phase 2 |
Docetaxel intermittent;Docetaxel standard of care |
| 44 |
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors |
Recruiting |
NCT05252390 |
Phase 1, Phase 2 |
NUV-868;Olaparib;Enzalutamide |
| 45 |
A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer |
Active, not recruiting |
NCT04033432 |
Phase 2 |
|
| 46 |
Immune Activation and Cellular Response From Enzalutamide Alone or With Radium223 in Men With Metastatic, Castration-Resistant Prostate Cancer |
Active, not recruiting |
NCT03344211 |
Phase 2 |
Enzalutamide |
| 47 |
A Single Arm Phase II Study of Bone-Targeted Sn-117m-DTPA in Symptomatic Castration Resistant Prostate Cancer With Skeletal Metastases |
Active, not recruiting |
NCT04616547 |
Phase 2 |
|
| 48 |
A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer |
Active, not recruiting |
NCT02703623 |
Phase 2 |
Abiraterone Acetate;Apalutamide;Cabazitaxel;Carboplatin;Prednisone |
| 49 |
Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment |
Active, not recruiting |
NCT02099864 |
Phase 2 |
Enzalutamide |
| 50 |
Addition of Pembrolizumab Upon Progression on Enzalutamide in Men With mCRPC |
Active, not recruiting |
NCT02312557 |
Phase 2 |
Enzalutamide |
|
